Currently Viewing:
Newsroom
Currently Reading
Patients With COPD Face High Risk of Adverse Drug Reactions Due to Multimorbidity
February 10, 2018 – Laura Joszt
CD4 Cell Counts Increased, Severe Immunodeficiency Decreased From 2002-2015
February 08, 2018 – Jaime Rosenberg
Atezolizumab Treatment Safe and Effective in Metastatic Urothelial Cancer Patients
February 08, 2018 – Kaitlynn Ely
What We're Reading: Medicare Extenders; Right-to-Try Opposition; Fetal Alcohol Disorders
February 07, 2018 – AJMC Staff
Study Shows Potential RNA Mimic Technology Can Block Pain
February 06, 2018 – Kaitlynn Ely
Genetic Testing a Must for Relatives of Cardiomyopathy Patients
February 05, 2018 – Kaitlynn Ely
What We're Reading: State Insurance Mandates; Universal Flu Vaccine; Fla. Opioid Bills
February 05, 2018 – AJMC Staff
New Study Analyzes Need for Biopsies During Follow-Up Care in Breast Cancer
February 01, 2018 – Kaitlynn Ely
Shifting Hospital Care to the Home Improved Quality of Life for Patients With COPD
January 29, 2018 – Laura Joszt

Patients With COPD Face High Risk of Adverse Drug Reactions Due to Multimorbidity

Laura Joszt
Multimorbidity is common in patients with chronic obstructive pulmonary disease (COPD), and is associated with high levels of polypharmacy, which can lead to an increased risk of adverse drug reactions.
Multimorbidity is common in patients with chronic obstructive pulmonary disease (COPD), and is associated with high levels of polypharmacy, which can lead to an increased risk of adverse drug reactions. According to a new study published in BMJ Open, patients with COPD are likely to be prescribed 3 or more drugs with similar potential side effects.

The paper assessed multimorbidity, polypharmacy, and risk of adverse drug reactions in patients in the UK Biobank, a large, population cohort that recruited 502,640 voluntary participants between the ages of 37 and 73 years from 2006 to 2010.

Multimorbidity was common among participants in the UK Biobank with COPD (85%), and 52% reported taking 5 or more medications. Many of the medications that contributed to the risks of adverse reactions were being used to treat other chronic illnesses, not COPD. The 6 potential adverse drug reactions that the authors identified were falls/fractures, constipation, urinary retention, central nervous system (CNS) depression, bleeding and renal injury.

“Our work shows that co-prescription of drugs with the potential for various adverse drug reactions is common,” lead author Peter Hanlon, MBChB, BMedSci, of the University of Glasgow, said in a statement.

Patients with COPD and cardiovascular disease had the highest percentage of taking 3 or more medications with a risk of falls or renal injuries, while patients with COPD and mental health conditions had the highest percentage of taking 3 or more medications with a risk of constipation, central nervous system depression, or bleeding.

“Our findings are important because it highlights the need for future research to examine the effects of this on healthcare outcomes,” said co-author Frances Mair, MBChB, of the University of Glasgow. “Going forward clinical guidelines need to start emphasizing the importance of the assessment of multimorbidity and adverse drug reaction risk.”

References

Hanlon P, Nicholl BI, Jani BD, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ Open. 2018;8(1):e018404. doi: 10.1136/bmjopen-2017-018404.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up